Taysha Gene Therapies, Inc. logo TSHA - Taysha Gene Therapies, Inc.

NEXT EARNINGS: Feb 25, 2026 (today) EPS Est: $-0.11 | Rev Est: $1.9M
Price: -- -- | CONSENSUS: Buy DETAILS
STRONG
BUY
0
BUY 12
HOLD 4
SELL 0
STRONG
SELL
0
| PRICE TARGET: $11.13 DETAILS
HIGH: $13.00
LOW: $8.00
MEDIAN: $11.00
CONSENSUS: $11.13
UPSIDE: 127.61%
Market Cap: 1.17B
Volume: 1,513,021
Avg Volume: 2,970,066
52 Week Range: 1.05-6.02
Sector: Healthcare
Industry: Biotechnology
Beta: 0.99
Last Dividend: $N/A
Exchange: NASDAQ
Country: US
Employees: 73
IPO Date: 2020-09-24
EPS (TTM): -0.36
P/E Ratio: -4.85
Revenue (TTM): 8.33M
Total Assets: 160.36M
Total Debt: 63.18M
Cash & Equiv: 139.04M
Rev Growth (5Y): 82.5%
EPS Growth (5Y): N/A
FCF Growth (5Y): N/A
ROCE: -66.5%
Debt/Equity: 0.88

Earnings History

Date EPS Actual EPS Est EPS Surprise Rev Actual Rev Est Rev Surprise
2025-11-04 $-0.09 $-0.09 0.0% $1.9M
2025-08-12 $-0.09 $-0.07 -28.6% $2.0M $1.7M +14.9%
2025-05-15 $-0.08 $-0.08 0.0% $2.3M $1.1M +112.3%
2025-02-26 $-0.07 $-0.08 +12.5% $2.0M $2.1M -1.5%
2024-11-13 $-0.09 $-0.08 -12.5% $1.8M $2.1M -12.9%
2024-08-12 $-0.09 $-0.10 +10.0% $1.1M $2.7M -58.2%
2024-05-14 $-0.10 $-0.11 +9.1% $3.4M $2.6M +33.2%
2024-03-19 $0.35 $-0.09 +488.9% $3.6M $2.6M +36.0%

Track Record

Statements >
Metric 2024 2023 2022 2021 2020 2019
Revenue 8.33M 15.45M 2.50M 0 0 0
Net Income (89.30M) (111.57M) (166.01M) (174.52M) (43.00M) (1.11M)
EPS -0.36 -0.96 -3.78 -4.64 -3.40 -0.03
Total Assets 160.36M 172.73M 126.28M 213.96M 258.88M 15,000
Total Debt 63.18M 61.11M 59.93M 63.09M 0 0
Cash & Equivalents 139.04M 143.94M 87.88M 149.10M 251.25M 0
Operating Cash Flow (81.22M) (73.02M) (88.39M) (117.04M) (30.73M) 135,000
Free Cash Flow (81.60M) (80.39M) (113.26M) (138.60M) (39.81M) 135,000
FCF per Share -0.33 -0.69 -2.58 -3.68 -2.25 0.00
Book Value 71.53M 74.94M 949,000 95.38M 251.30M (135,000)
Cash & ST Investments 139.04M 143.94M 87.88M 149.10M 251.25M 0
ROC Equity -1.25 -1.49 -174.94 -1.83 -0.17 N/A